Arguably, one of the most challenging issues for technology transfer and IP professionals is choosing which technologies to move through the pipeline, how to prioritize the best of the best, which assets to back-burner or shelve entirely, and where to spend your limited budget as well as your staff’s limited time.
Each decision your team makes can run the risk of degrading relationships with researchers, or on the other end of the spectrum wasting tens of thousands of scarce dollars on technologies that just aren’t commercially viable. Unfortunately, despite the huge stakes in patenting an invention or backing a start-up, there are no infallible methods to predict what will end up going the distance to the marketplace. So how do you make these tough decisions and make sure you back more winners and fewer losers?
For starters, join us for a powerful, high-level distance learning program led by our A-level team of four experts who have been through or advised on the technology assessment and decision-making process countless times. They’ll share their time-tested advice and specific, practical guidance to help you identify the winners in your portfolio, justify your decisions to faculty and other key stakeholders, and boost your office’s efficiency by applying more staff time and budget dollars to innovations with true market potential.
Pre-launch Considerations for University Innovations:
Focus Your TTO Staff and Budget on the Winners
By adopting our panel’s proven best practices, you will achieve higher success rates, more effective use of staff time and patent budgets, and better relationships with faculty inventors. You’ll also slash wasted time and effort, bring a higher percentage of high-promise innovations forward, and enable more confident decision-making when faced with competing priorities. Our esteemed panel will discuss all four key elements that should inform your patent and start-up assessments:
- Market Evaluation
Does the technology/science/product address a critical unmet need and market opportunity?
- Technology Evaluation
Does the technology/science/product data justify embarking on a development/commercialization plan?
- IP Assessment
Is there a proprietary position that allows the product to return value to the investor and/or the university?
- Business and Financing Plan
What are the near and medium term valuation milestones in the development of the product or company, and how will the company or university finance to those milestones?
Your Panel of Presenters:
Margaret K. Offermann, MD, PhD, is a founding managing partner at The Salutramed Group, Inc, a consulting organization for senior executives in life science companies, academic institutes, technology transfer offices and healthcare organizations. From 1989-2007, she was on the faculty of Emory University where she rose to the rank of Professor of Hematology and Oncology, co-director of the MD, PhD training program, Associate Director of the Postgraduate Training Program in Hematology and Oncology and Associate Director of the Winship Cancer Institute. From 2007-2010, she served as Deputy National Vice President for Research at the American Cancer Society, providing executive leadership for both intramural and extramural research programs and serving as a spokesperson for the organization. She has served on national and regional boards and is President-Elect for the Federation of American Societies for Experimental Biology (FASEB), a federation of 26 professional societies representing over 100,000 scientists throughout the United States that is celebrating its centennial year. FASEB advances biological science through collaborative advocacy for research policies that promote scientific progress and education.
T. (Teo) Forcht Dagi, MD, partner with HLM Venture Partners, is currently a director of Aventura, Axela Biosensors, Inc. and Queen’s University Medicine and a board observer at Teladoc. He chairs the School of Medicine, Dentistry and Biomedical Sciences at Queen’s University Belfast, Northern Ireland. Prior to joining HLM in 2006, he was a Managing Partner of Cordova Ventures in Atlanta and oversaw its life sciences and health care portfolio. Prior to that, he taught and practiced neurosurgery on the faculties of Harvard, Brown and Georgetown Universities and the National Institutes of Health.
Jack Capers, partner with King and Spalding in Atlanta and the Silicon Valley, is a member of the firm’s Corporate Practice Group. Mr. Capers advises life sciences companies at all stages of development on matters related to product development, financings, collaborations and joint ventures and sale transactions. He also advises boards of directors of life sciences companies on corporate governance issues including the fiduciary duties of directors of early-stage life sciences companies. Mr. Capers was named one of The Best Lawyers in America 2012, one of America’s Leading Lawyers for Business 2012 by Chambers USA, and one of Georgia’s Super Lawyers 2012 by Atlanta Magazine.
Russell M. Medford, M.D., Ph.D., founding managing partner of The Salutramed Group, Inc, (www.salutramed.com) an Atlanta and Boston based consulting firm that provides actionable insight for senior life science, foundation and institutional executives and Boards of Directors to address critical issues of corporate and institutional strategy, growth, risk mitigation, value creation and public policy. He has extensive experience in the development and translation of advanced science into novel, first-in-man therapeutics addressing critical unmet medical needs. Dr. Medford has built and led multiple research and development biotechnology companies, from early startup through IPO into advanced NASDAQ traded companies engaged in multiple, late-stage international clinical trials. These included the cardiovascular and metabolic disease company, AtheroGenics, Inc. (AGIX), as its scientific co-founder (as an Associate Professor of Medicine at the Emory University School of Medicine), advancing to corporate Board Director and CEO, raising over $500 million in both the private and public equities markets, and the antiviral company Inhibitex, Inc. (INHX) as a founding Board Director until its recent sale to a major pharmaceutical company for $2.5 billion in cash. He is currently Chairman of Salutria Pharmaceuticals, LLC, developing new drugs for multiple sclerosis and other inflammatory diseases and is a member of the Board of Directors of Biotechnology Industry Organization (Washington DC), Georgia BIO, the National Health Museum and the Petit Institute of Bioscience and Bioengineering of the Georgia Institute of Technology.